share_log

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

SEC announcement ·  Feb 26 06:40
Summary by Moomoo AI
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger 12-month share buyback plan with a budget of up to DKK 20 billion. From February 6 to April 30, 2024, the company plans to repurchase B shares worth up to DKK 2.1 billion. As of February 23, 2024, Novo Nordisk has repurchased 609,000 B shares at an average price of DKK 836.89 per share, totaling DKK 509,663,002. These transactions have increased the company's treasury shares to 47,149,707 B shares, representing 1.0% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 63,400 people worldwide.
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger 12-month share buyback plan with a budget of up to DKK 20 billion. From February 6 to April 30, 2024, the company plans to repurchase B shares worth up to DKK 2.1 billion. As of February 23, 2024, Novo Nordisk has repurchased 609,000 B shares at an average price of DKK 836.89 per share, totaling DKK 509,663,002. These transactions have increased the company's treasury shares to 47,149,707 B shares, representing 1.0% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 63,400 people worldwide.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more